Calendario de vacunaciones de la Asociación Española de Pediatría: recomendaciones 2015

Moreno-Pérez, David; García, Francisco José Álvarez; Fernández, Julio Blanco; Ortega, María José Cilleruelo; Rauet, J.M. Corretger; Sánchez, Nuria García; Merino, Ángel Hernández; Matos, T. Hernández-Sampelayo; Moína, M. Merino; Castillo, Luis Ortigosa del; Ruiz–Contreras, Jesús

doi:10.1016/j.anpedi.2014.10.019

Cited by 15 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The sensitivity analysis showed that assumption 3, with the administration of one dose of the vaccine only to sick individuals at a retail price and assuming a capitalization factor of 6%, is the most cost-effective. This assumption is not consistent with the recommendations of the Spanish Society of Pediatrics, 4 which suggests that greater effectiveness is achieved with two doses.…”

Section: Discussioncontrasting

confidence: 49%

“…[1][2][3][4][5]7 Outbreaks in schools have been observed with a single dose and coverage close to 99%. 5 Also with a single dose, the age of varicella onset may be delayed.…”

Section: Discussionmentioning

confidence: 99%

“…The Spanish Society of Pediatrics' immunization schedule indicates the first dose for 1-year-old infants and a booster dose as of 2-3 years. 4 In 2016, the varicella vaccine was introduced at a national level in Spain for children aged 15 months old with a booster dose at 3-4 years. 6 Some countries provide the measles, mumps, rubella and varicella (MMRV) vaccine to infants with the corresponding booster dose.…”

Section: Introductionmentioning

confidence: 99%

“…At present, in Spain, there are two live, attenuated virus (OKA strain) vaccines. 1,4 In the Autonomous Community of Aragón (1325 million inhabitants in 2014), the vaccine was introduced in the immunization schedule in 2007 for children aged 11 Original article administered free of charge by the Public Health System. Two vaccine doses provide an overall coverage of 100%, 5 and are very well-tolerated.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A cost-benefit analysis of varicella vaccination in Aragón

Blasco

Pérez-Aramendía

2017

Arch Argent Pediat

View full text Add to dashboard Cite

Background. Varicella, a contagious and infectious disease that is usually benign in children, may become complicated among adults and vulnerable children and may even be life-threatening. There are effective vaccines. A retrospective study was conducted about costs and resulting hospitalizations related to this disease in the population of Aragón in the 2004-2014 period. Costs were compared to the expenses that would have been incurred if those people had received the vaccine and also to the expenses of vaccinating the 1-year-old population over the entire period. A cost-benefit analysis was done to assess the economic impact of varicella vaccination. Method. Data for the 11-year period were provided by the Autonomous Community of Aragón (Spain) and included annual varicella incidence, hospital discharges of varicella cases, costs of primary health care visits and hospitalizations for each year, costs of each workday as per the minimum annual salary and of drugs used). Capitalized costs were estimated and compared to capitalized expenses of vaccination, and a sensitivity analysis was performed. Results. A benefit-cost ratio of 1.6 was obtained considering that all children who had varicella had been vaccinated and had received a booster dose. A benefit-cost ratio of 1.24 was obtained considering that the vaccine had been administered to every 1-year-old individual at a price of EUR 28.59 per vaccine. Over the 11-year period, 53% of hospitalizations corresponded to children younger than 5 years old. Conclusions. Public campaigns for the immunization of children younger than 4 years old with 2 doses lead to cost savings and are cost-effective because the vaccine price results in a benefit-cost ratio greater than 1. A major reduction is expected in the number of hospitalizations among children aged 3-4 years.

show abstract

Section: Discussioncontrasting

confidence: 49%

“…[1][2][3][4][5]7 Outbreaks in schools have been observed with a single dose and coverage close to 99%. 5 Also with a single dose, the age of varicella onset may be delayed.…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A cost-benefit analysis of varicella vaccination in Aragón

Blasco

Pérez-Aramendía

2017

Arch Argent Pediat

View full text Add to dashboard Cite

show abstract

“…), se ha estimado que la varicela es la causa más frecuente de muerte prevenible por vacunación. 4 En 2016, se incluyó en toda España la vacuna contra la varicela a los 15 meses y el refuerzo a los 3-4 años. 6 En algunos países, se administra la vacuna combinada contra sarampión, paperas, rubeola y varicela (measles, mumps, rubella and varicella; MMRV, por sus siglas en inglés) a lactantes con su consiguiente refuerzo.…”

Section: Introductionunclassified

Estudio coste-beneficio de la vacunación contra varicela en Aragón

Blasco

Pérez-Aramendía

2017

Arch Argent Pediat

View full text Add to dashboard Cite

Changes in the pneumococcal disease-related hospitalisations in Spain after the replacement of 7-valent by 13-valent conjugate vaccine

Georgalis

Mozalevskis

Aragón

et al. 2016

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

In Spain, anti-pneumococcal vaccination is recommended for all children under 2 years old, high-risk groups and adults ≥65 years old. However, it is not funded in most autonomous communities. This study aims to compare pneumococcal disease hospitalisation rates between Period 1 (2007-2009), when 7-valent (PCV7) vaccine was available, and Period 2 (2011-2013), after the change to 13-valent (PCV13) vaccine in Spain. Data on hospitalisations were obtained from the National Registry of Hospitalisations. We calculated hospitalisation rates (HRs) and hospitalisation rate ratios (HRRs) among periods by age group and autonomous community, for all and by clinical presentation. From 138,361 patients hospitalised, 83,528 (60.4 %) were males. The median age was 73.8 years. The most common clinical presentation was pneumonia (133,204 hospitalisations; 96.3 %), followed by septicaemia (7053 hospitalisations; 5.1 %) and meningitis (3182 hospitalisations; 2.3 %). In Period 2, hospitalisations among children <5 years old decreased for pneumonia [HRR: 0.37; 95 % confidence interval (95 % CI): 0.35 to 0.39] and meningitis (HRR: 0.53; 95 % CI: 0.44 to 0.65). For adults ≥65 years old, pneumonia (HRR: 0.49; 95 % CI: 0.49 to 0.50) and peritonitis (HRR: 0.34; 95 % CI: 0.19 to 0.63) hospitalisations decreased and septicaemia hospitalisations (HRR: 1.27; 95 % CI: 1.18 to 1.36) increased. Significant changes in HRs for pneumococcal disease were observed even without an integrated and continuous vaccination programme after the introduction of PCV13, especially in children <5 years old and for pneumonia. The impact of the PCV13 adult vaccination new recommendations on the septicaemia increase reported should be evaluated in the future.

show abstract

Calendario de vacunaciones de la Asociación Española de Pediatría: recomendaciones 2015

Cited by 15 publications

References 24 publications

A cost-benefit analysis of varicella vaccination in Aragón

A cost-benefit analysis of varicella vaccination in Aragón

Estudio coste-beneficio de la vacunación contra varicela en Aragón

Changes in the pneumococcal disease-related hospitalisations in Spain after the replacement of 7-valent by 13-valent conjugate vaccine

Contact Info

Product

Resources

About